Please assess the completion status of the following clinical trial:

Trial Title: Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject aged 18 years and older referred for evaluation of possible stroke.~2. Subject receives Computed Tomography Angiography (CTA) imaging for the assessment of stroke.~3. Subject or Legally Authorized Representative has the ability to provide informed consent and comply with the protocol.~Exclusion Criteria:~1. Head CT findings consistent with acute primary intracranial hemorrhage (ICH), etc.~2. Subjects with occlusions in the distal or posterior circulation arteries.~3. Subjects who underwent partial or full craniotomy~4. Additional intracranial pathologies present (tumor, hydrocephalus, etc.)~5. Anticipated insufficient time to acquire a complete TCD scan as described by the protocol~6. Subjects who have a physical limitation preventing placement of the system.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort X (Type: None): Phase 0 will include up to 20 subjects in Cohort X (TCD). This phase is for training and feasibility purposes only and data collected will not be used in the final analysis.
- Cohort Y (Type: None): Phase 0 will include up to 20 subjects in Cohort Y (No TCD). This phase is for training and feasibility purposes only and data collected will not be used in the final analysis.
- Cohort A (Type: None): Both Phase 1 and Phase 2 of the study will enroll Cohort A (LVO TCD). Cohort A will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
- Cohort B (Type: None): Both Phase 1 and Phase 2 of the study will enroll Cohort B (Non-LVO TCD). Cohort B will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
- Cohort C (Type: None): Both Phase 1 and Phase 2 of the study will enroll Cohort C (LVO No-TCD). Cohort C will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
- Cohort D (Type: None): Both Phase 1 and Phase 2 of the study will enroll Cohort D (Non-LVO No-TCD). Cohort D will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2

Based on this trial design, predict the completion outcome and termination type (if applicable).